Date: 2013-12-02
Type of information: Development agreement
Compound: IMX101 (recombinant vaccine against Helicobacter pylori)
Company: ProJect Pharmaceutics (Germany) ImevaX (Germany)
Therapeutic area: Infectious diseases
Type agreement: development
Action mechanism:
Disease: Helicobacter pylori infection
Details: * On December 2, 2013, ProJect Pharmaceutics has announced that it has signed a development agreement with ImevaX, a spin-off project from the research group of Prof. Dr. Markus Gerhard from the Technische Universität München, Institute for Medicinal Microbiology, Immunology and Hygiene, aimed at developing a formulation for a recombinant vaccine against Helicobacter pylori. IMX101 is a multicomponent vaccine, making the formulation development particularly challenging. The contract covers activities in developing a rational formulation based on ProJect Pharmaceutics´ Predictive Formulation Analytics. This technology offers an innovative scientific approach for designing optimized protein formulations by determining the most favorable composition for the native structure of the protein with regard to its intra- and intermolecular physicochemical properties. By analyzing the response to certain excipients the most promising formulation candidates can be identified quickly and reliably reducing the need for extensive stability testing. Promising formulation candidates have successfully been evaluated and are continuously optimized within the development program since its launch in mid 2013.
ImevaX is planned to be founded as a biotech company in 2014.
Financial terms: Financial terms of the current agreement are not disclosed.
Latest news:
